InflaRx (NASDAQ:IFRX - Get Free Report) was the recipient of a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 216,500 shares, a growth of 37.9% from the November 30th total of 157,000 shares. Based on an average daily volume of 243,600 shares, the short-interest ratio is currently 0.9 days.
Wall Street Analyst Weigh In
Separately, HC Wainwright restated a "buy" rating and issued a $8.00 target price on shares of InflaRx in a report on Friday, December 20th.
Read Our Latest Analysis on IFRX
InflaRx Price Performance
Shares of IFRX traded up $0.05 during trading hours on Monday, hitting $2.64. The stock had a trading volume of 215,593 shares, compared to its average volume of 187,703. The firm has a market capitalization of $155.44 million, a PE ratio of -2.44 and a beta of 1.67. InflaRx has a 12 month low of $1.16 and a 12 month high of $2.82. The stock has a fifty day moving average price of $2.05 and a 200 day moving average price of $1.71.
About InflaRx
(
Get Free Report)
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.
Recommended Stories
Before you consider InflaRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InflaRx wasn't on the list.
While InflaRx currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
